Plain-English translation of NCT06858280 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called patiromer to help people on chronic dialysis manage their potassium levels. Right now, dialysis patients must follow a very strict low-potassium diet, which means avoiding many healthy foods like fruits, vegetables, fish, and dairy products. The goal is to see if this medication could help keep potassium at safe levels while allowing patients to eat a wider variety of foods and enjoy better nutrition and quality of life.
Dialysis patients face an impossible dietary puzzle: they must restrict potassium to prevent dangerous heart problems, but this restriction cuts out many nutritious foods and makes meals unappetizing. At the same time, they have to limit fluid, sodium, and phosphate intake, leaving very little they can actually eat. This medication is being tested to see if it can help control potassium in the body itself, so patients wouldn't have to be quite as strict about avoiding healthy foods.
You likely qualify if…
You likely don't qualify if…
You would take either the new medication or a placebo (a dummy pill with no active ingredient) every day for three months while continuing your regular dialysis schedule. During this time, you would continue your current diet but may be asked about your quality of life, nutrition, and how well you're managing your potassium levels. The study will compare your potassium levels and how you feel while taking the medication versus the placebo to see if the treatment helps, and half of participants will randomly receive the real medication while half receive the placebo.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Italy
Phase
Large-scale testing
Sponsor
Mario Negri Institute for Pharmacological Research
Enrollment target
~40 participants
Started
July 2025
Primary completion
July 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Piero L Ruggenenti, M.D.
Mario Negri Institute for Pharmacological Research
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.